Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
Aptevo Therapeutics announced a poster presentation during the 64th ASH Annual Meeting on December 11, 2022, focusing on its lead candidate APVO436 for treating acute myeloid leukemia.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aptevo Therapeutics announced a poster presentation during the 64th ASH Annual Meeting on December 11, 2022, focusing on its lead candidate APVO436 for treating acute myeloid leukemia.
The presentation will include updated results from a Phase 1 study evaluating the efficacy of this novel bispecific molecule designed for relapsed and refractory cases. The session will be led by Dr. Justin M. Watts from the University of Miami's Sylvester Comprehensive Cancer Center.
Positive
- Acceptance to present at a prestigious conference indicates credibility and interest in APVO436.
- Potential to advance the development of APVO436, which targets a critical area in leukemia treatment.
Negative
- None.
Details
News Market Reaction – APVO
The recorded move for APVO in the trading session of this news was -0.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to Present New Data from On-Going Phase 1b Trial Evaluating Lead Candidate APVO436 for the Treatment of Acute Myeloid Leukemia
SEATTLE, WA / ACCESSWIRE / November 3, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced acceptance of a poster presentation at 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13 in New Orleans, Louisiana. Details of the presentation, which will be presented live, are as follows:
Title: "Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome"
Date/Time: Sunday, December 11, 2022, 6:00 PM-8:00 PM
Presenter: Justin M. Watts, MD, Associate Professor of Medicine Section Chief, Leukemia, Pap Corps Endowed Professor in Leukemia, Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. Aptevo is seeking to improve treatment outcomes of cancer patients. For more information, please visit www.aptevotherapeutics.com.
CONTACT:
Miriam Weber Miller
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628
SOURCE: Aptevo Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/723685/Aptevo-Therapeutics-Announces-Poster-Presentation-at-the-64th-American-Society-of-Hematology-Annual-Meeting-and-Exposition
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.